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Background: Uterine fibroids are the most common tumour in women of reproductive age. By the time they are
50-years-old around 80% of women will have developed one. Of these, around half will experience symptoms
which will impact negatively on their quality of life. Hysterectomy is the traditional treatment for women with
symptomatic fibroids. For women who do not wish to undergo a hysterectomy, two invasive treatments are
commonly available: myomectomy or uterine artery embolization (UAE).
Design: FEMME is a pragmatic, randomised, open, multi-centre trial examining the quality of life menstruating
women with symptomatic fibroids experience after treatment with UAE or myomectomy.
Methods: After providing informed consent, 216 women with symptomatic fibroids from 43 NHS Hospital Trusts
and Health Boards across the United Kingdom will undergo randomisation by a centralised computer system to
treatment by either UAE or myomectomy. A minimisation algorithm will be used in order to balance the groups
with respect to the following three parameters: the longest dimension of the largest fibroid, the number of fibroids
present, and whether the woman currently desires pregnancy.
Using validated questionnaires the women’s quality of life will be compared between groups at six months, one year,
two years and four years post-procedure, taking into account pre-procedure scores. An economic evaluation will be
conducted alongside the trial to determine the cost-effectiveness of UAE compared with myomectomy.
Validated diaries will also be used to compare menstrual blood loss at the same time-points. The plasma concentration
of Anti-Müllerian hormone (AMH), which will act as a proxy measurement of ovarian reserve, will be recorded before
the woman has her procedure and then again at six weeks, six months, and twelve months afterwards. Re-intervention
rates will be recorded.
Discussion: The FEMME trial’s primary outcome is the quality of life women with symptomatic uterine fibroids
experience two years after they have been treated with either UAE or myomectomy, as measured by the
disease-specific Uterine Fibroid Symptom Quality-of-Life (UFS-QoL) questionnaire.
Trial registration: Current Controlled Trials registration number: ISRCTN70772394, registered on 2 March 2013.
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Why is there a need to determine whether treatment with
uterine artery embolisation or myomectomy is most
efficacious in improving the quality of life of women with
uterine fibroids?
Uterine fibroids are the most common tumour in women
of reproductive age and increase in prevalence as the
woman gets older. By the time they are 50-years-old,
around 80% of women will have developed a fibroid.
Approximately half of women with fibroids experience
significant symptoms which can include heavy menstrual
bleeding (HMB), pain on intercourse, abdominal pain, and
a feeling of pressure, all of which can impact significantly
on the woman’s quality of life [1].
The symptoms experienced by the woman with fibroids
may vary depending on the position, size and number of
fibroids. Intramural fibroids are the most common form of
fibroid but are frequently asymptomatic. Subserosal fibroids,
located on the outer surface of the uterus, can become very
large and create feelings of bulkiness. Submucosal fibroids
project into the uterine cavity and are associated with HMB.
As they may distort the uterus and change the local morph-
ology of the uterine tissue, some clinicians believe that the
presence of fibroids may have a negative impact on fertility
[2]. The Hospital Episode Statistics state that there were
just under 31,000 Finished Consultant Episodes of women
with fibroids of the uterus between 2012 and 2013 in the
United Kingdom. The majority of these women were aged
between 40 and 54-years-old [3].
Women with symptomatic fibroids often respond poorly to
drug management or risk unacceptable side effects from
hormonal preparations [4], so generally the use of these
pharmaceuticals is limited to reducing the fibroid bulk and
relieving the symptoms prior to surgical intervention. The
traditional treatment for symptomatic fibroids is hysterectomy,
but with many women associating their uterus with their fem-
ininity and sexuality, an increasing number of women with
fibroids are questioning whether hysterectomy for a benign
condition is necessary and many are seeking alternatives.
In the National Health Service (NHS) there are two
womb-sparing procedures available to treat uterine fi-
broids; uterine artery embolisation (UAE) and myomec-
tomy. In UAE, an arterial catheter is used to introduce
an embolic agent into the blood vessel supplying the
uterus. This blocks the blood flow to the fibroid causing it
to infarct (die), so relieving the symptoms of the fibroid.
Myomectomy is the surgical removal of the fibroid, and
depending on the size and position of the fibroid, this can
be undertaken by a variety of routes including laparo-
scopic, hysteroscopic, or by a laparotomy.
Previous work comparing UAE with myomectomy
The use of UAE in women who may wish to conceive is con-
troversial within some sections of the medical community.Some authors are concerned by the reduction in blood
flow to the ovary that can occur if there are significant
connections between the ovarian and uterine arteries,
which may result in decreased ovarian function [5]. The
extent of this decreased function, how long it is main-
tained for, and even if it occurs at all, is disputed [6,7].
Whilst generally regarded as safe [8], the caution inherent
in the guidelines drawn up when UAE was still in its in-
fancy has led to a further reluctance in some circles to use
UAE in women who may wish to try to conceive at some
point. As a result of this, trials generally excluded women
who are seeking fertility.
One small (n = 121) single centre, randomised, clinical
trial from the Czech Republic compared myomectomy
with UAE in women with intramural fibroids [9]. These
authors concluded that UAE was less invasive, but as ef-
fective and safe as myomectomy for treating the symptoms
of fibroids. The REST trial [10] randomised a total of 157
women in a 2:1 ratio between UAE and myomectomy be-
fore assessing the quality of life (QoL) at five years with the
Short Form 36 (SF-36) general health survey. Secondary
measures included complications, adverse events, and the
need for further intervention. These authors reported that
there were no significant differences in the reported QoL
between the groups at five years. However, there was a sig-
nificantly greater re-intervention rate after five years for
treatment failure or complications in the UAE arm over
the myomectomy arm. This negated the initial cost benefit
of UAE over surgery at 12 months and made both treat-
ments cost-neutral at five years [10].
A pilot study for the FEMME trial (the FUME study [11])
was conducted at St George’s Hospital, London, United
Kingdom. In this study 160 women with symptomatic uter-
ine fibroids were randomised to UAE or myomectomy and
the change in their QoL, hospital stay, complication rates,
and need for re-intervention were measured at one year
post-procedure. The authors reported that by one year
there was no difference in the improvement of the QoL
women experienced in the myomectomy and UAE arm
but, like the REST trial, there was a higher intervention
rate in women who had undergone a UAE [11].
With increasing pressure on ever diminishing NHS bud-
gets the cost-effectiveness is increasing in importance to
commissioners and Trusts when deciding which treatment
options should be available. The average length of stay in
hospital post-hysterectomy is 4.4 days [10], and it is not un-
usual for women to require an additional three months to
recuperate before returning to their normal lives. The
average stay in hospital post-myomectomy is 3.6 days and,
depending on the route used, the post-procedure recuper-
ation time can be up to several weeks. With its minimally
invasive nature, the mean length of hospital stay post-
UAE is one day, with a return to normal life typically
within a couple of weeks. Whilst superficially this may
McPherson et al. Trials 2014, 15:468 Page 3 of 10
http://www.trialsjournal.com/content/15/1/468suggest a significant economic advantage for UAE,
the higher re-intervention rates compared with hys-




The FEMME trial is a randomised, open, multi-centre
trial comparing UAE with myomectomy in women with
symptomatic uterine fibroids.
Primary outcome
The FEMME trial’s primary outcome is to measure the
QoL women with symptomatic uterine fibroids experience
two years after they have been treated with UAE or myo-
mectomy, through the disease-specific Uterine Fibroid
Symptom Quality of Life (UFS-QoL) questionnaire.
Secondary outcomes
The FEMME trial’s secondary outcomes are:
1. EuroQoL EQ-5D score and visual analogue scale
score;
2. Menstrual blood loss, assessed using the Pictorial
Blood loss Assessment Chart (PBAC). This is a
validated and well-used assessment of menstrual
blood loss in women with uterine fibroids;
3. Pregnancy outcomes - pregnancy will be reported by
the woman in the first instance. The research nurse
or trial coordinator will collect further information
with respect to timing of pregnancy, biochemical
pregnancy (positive pregnancy test), incidence of
miscarriage, outcome of pregnancy, gestational age at
delivery or miscarriage, complications of pregnancy,
and labour;
4. Adverse events - all adverse outcomes considered to
be related to the study protocol or intervention will
be collected. Since adverse outcomes may occur
many months after intervention, these data will
continue to be collected throughout the study;
5. Length of hospital stay;
6. Time to return to work or usual activity;
7. Further treatment for incomplete removal or
recurrence of symptoms, including hysterectomies;
8. Ovarian reserve - blood samples will be taken
from the women in each treatment arm for the
measurement of the plasma levels of Anti-Müllerian
hormone (AMH), a compound used as a proxy
measurement of ovarian reserve, to determine if
there is any difference at six weeks, six months,
and twelve months post-procedure.
The time-points at which these follow-ups are performed
are shown in Table 1.With an increasing number of women seeking an alter-
native to hysterectomy, this timely trial will investigate the
role of UAE and myomectomy in treating women with
symptomatic uterine fibroids, and so inform women as to
the most appropriate treatment for them.
Recruitment
Patients will be recruited from multiple (more than 40)
secondary and tertiary centres throughout the United
Kingdom, including specialist centres, district general,
and large teaching hospitals. Centres will be able to par-
ticipate in the FEMME trial if a care pathway is present
which allows eligible women presenting at the site to be
randomised between UAE and myomectomy.
Eligibility criteria
A woman is eligible to be considered to take part in the
FEMME trial if:
1. They have menstruated within the preceding twelve
months and present with symptomatic fibroids
which the reviewing clinician feels can be treated
equally well with UAE or myomectomy;
2. The woman has not undergone a previous
myomectomy via a laparotomy or a previous UAE;
3. They are over 18 years of age, not pregnant, and are
prepared to accept a hysterectomy in an emergency;
4. There is no evidence of malignancy, pelvic
inflammatory disease, or significant (in the opinion
of the reviewing clinician) adenomyosis.
Full eligibility criteria are shown in Figure 1.
Patient information
Women will be identified primarily by gynaecologists in
dysmenorrhea or general gynaecology clinics, but a small
minority may be referred directly to an interventional radi-
ologist. In the latter case, potential participants will need
to be reviewed by a gynaecologist to ensure they are suit-
able for myomectomy.
Depending on local practice and staff availability, the re-
ferral letters may be screened by the research nurse who
will bring to the gynaecologist’s attention those women
whose symptoms are suggestive of uterine fibroids and
who may be eligible to take part in the FEMME trial.
After review, should the gynaecologist agree that uter-
ine fibroids are the likely underlying cause of the de-
scribed symptoms, they can request the nurse sends out a
Research Ethics Committee (REC)-approved participant
information sheet (PIS) and covering letter in advance.
This will allow the woman to be aware of the FEMME
trial before she attends the clinic for her appointment.
This stage is optional and dependent on local practice and
gynaecology agreement.
Table 1 Time-points at which outcomes are recorded
Outcome measure Prior to randomisation Before discharge 6 weeks 6 months 1 year 2 years 4 years
UFS-QoL/EQ-5D × × × × ×
Pregnancy × × × ×
Outcomes of pregnancy As reported by participant
PBAC × × × × ×
Fertility potential × × × ×
Resource usage (clinical) × × ×
Technical success ×
Serious adverse events As reported by clinician/participant
Further treatment × × × ×
Legend:
UFS-QoL: Uterine Fibroid Symptoms – Quality of Life.
EQ-5D: EuroQol – 5D score and visual analogue scale score.
PBAC - the Pictorial Blood loss Assessment Chart.
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by a qualified gynaecologist. Following confirmation of the
presence of fibroids, if the gynaecologist feels that these
will respond equally well to UAE or myomectomy, then
the gynaecologist will make the initial approach to the
women to make them aware of the FEMME trial. If the
woman expresses an interest in taking part in the FEMME
trial then an approved member of the local research team
will discuss the protocol with them and answer any quer-
ies they may have.
Consent
Consent will be obtained from any potential participant
in compliance with the requirements of the REC before
they are included in the trial. Any potential participant
will only be approached by an approved member of the
local research team. The potential participant will be
given a copy of the REC-approved PIS, setting out the
nature and purpose of the study, alongside the possible
risks and benefits of taking part. The approved member of
the local research team will fully discuss the trial with the
potential participant and answer any questions they may
have prior to consent being taken. Any potential partici-
pant will be informed that they can withdraw from the trial
at any point without having a give a reason why. Should
they wish to withdraw, then the patient will be reassured
that the medical care they receive will not be affected in
any way. The patient’s consent will be recorded on a REC-
approved consent form and countersigned by the approved
member of the local research team. Once signed and dated
by all parties, the participant will be given a copy of the
consent form for their own records.
Randomisation
In order to reduce bias as far as possible, following in-
formed consent but before randomisation, the partici-
pant will be given the validated QoL questionnaires (theUFS-QoL and the EuroQoL EQ-5D) and asked to complete
them. Once completed and returned to the clinical staff,
the patient’s details will be entered onto a centralised on-
line system which will allocate the patient to their treat-
ment (myomectomy or UAE). A minimisation algorithm
will be used to ensure that the groups are balanced as
evenly as possible with respect to treatment group and
also the following variables: the longest dimension of the
largest fibroid (under 7 cm or over 7 cm), the number of fi-
broids present (1 to 3, 4 to 10, over 10), and if the woman
desires pregnancy (yes or no).
The number and size of the fibroids present will be deter-
mined by imaging with either: magnetic resonance imaging
(MRI) (contrast enhanced and/or non-contrast enhanced),
ultrasound (vaginal or trans-abdominal), or hysteroscopy.
Should a participant have been randomised on any
type of imaging other than MRI then, if local capacity al-
lows, an MRI scan will be requested prior to the patient
undergoing their procedure. After randomization, blood
will be drawn into two BD Vacutainer® serum separator
tubes (SST, BD, The Danby Building, Edmund Halley
Road, Oxford Science Park, Oxford OX4 4DQ, England)
for the proxy measurement of ovarian reserve. These
blood samples will be placed into a Royal Mail Safebox™
and sent to Birmingham University’s Human Tissue
Repository. Upon receipt, the blood samples will be
transformed into serum and stored in a secure biobanking
facility at −80°C until analysis. Finally, the participant will
be given a copy of the menstrual blood loss diary to take
away with them and asked to complete it when they start
their next period. Upon completion this blood loss diary
will be returned to the trials office in a prepaid envelope
provided.
Treatment
A pregnancy test will be performed immediately prior to
treatment. As FEMME is a pragmatic trial, other than
Figure 1 FEMME trial eligibility flow chart. UAE, uterine artery embolization.
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the woman receives is the clinician’s normal practice. This
means that if the woman is randomised to a myomectomy
this can be of any type including laparoscopic, hystero-
scopic, or by a laparotomy. Similarly, should the woman
be randomised to UAE, this is performed according to the
interventional radiologist’s normal practice. Information
collected at the time of the procedure will include details
of the treatment received, any adverse events experienced
by the participant, and the length of in-patient stay.
Follow-up
The time-points when the various outcomes are re-
corded are shown in Table 1. At each time-point, details
of any pregnancy will be collected alongside information
on any resource use including:
1. The number and reason of any additional out-patient
visits and/or primary care consultations;
2. Any additional procedures and inpatient stays;
3. The type and dose of any medications received;
4. Any further tests and interventions received;
The information collected at each time-point is sum-
marised in Figure 2, the study schema.
Outcome measures
The primary outcome for the FEMME study is the health-
related quality of life (HRQL) score from the UFS-QoL
questionnaire recorded two years post-procedure.
Primary and interim analysis
HRQL scores from the UFS-QoL will be analysed using a
linear model (analysis of covariance) with estimates of dif-
ference between groups adjusting for the baseline score.
Results of the primary outcome score at other time-points,
along with the results of other continuous-type measure-
ments (for example, symptom severity score from the
UFS-QoL questionnaire, EQ-5D and Blood Loss scores)
will be analysed in a similar fashion. Further analysis of
continuous measures will be undertaken using a repeated
measure multilevel model to examine any differential ef-
fect over time [12].
Dichotomous measures (for example, pregnancy or re-
intervention rates) will be analysed using relative risks
and chi-squared tests at each time-point. Variables, in-
cluding pregnancy and any re-intervention, will also be
explored using standard time-to-event analysis methods
(log-rank test). All analyses will be performed using the
intention-to-treat principle, with effect sizes presented
as point estimates and corresponding 95% confidence
intervals. A more comprehensive analysis plan will be
made available for review by the Data Monitoring
Committee (DMC).An interim report, including the analysis of major end-
points, will be provided in strict confidence to the Data
Monitoring and Ethics Committee at intervals of at least
12 months, or as requested by the DMC.
Handling missing data
In the first instance analysis will be completed on received
data, with every effort made to follow-up participants
(even after protocol treatment violation) to minimise any
potential bias. Sensitivity analysis of the primary outcome
measure, including imputed values for missing responses,
will be performed to determine the robustness of the
results obtained. Methods based on multiple imputation
will be used.
Subgroup analysis
Subgroup analyses are limited by statistical power and can
produce spurious results, particularly if numerous analyses
are undertaken. For this reason, any subgroup analysis will
be limited to the minimisation variables listed in the Initial
assessment and randomisation section. Effects within sub-
groups will only be investigated further if suitable tests for
interaction (by including the relevant interaction param-
eter in the regression model) are statistically robust.
Economic evaluation of embolisation compared with
myomectomy
An economic evaluation will be conducted alongside the
clinical trial to determine the relative cost-effectiveness of
UAE compared to myomectomy from the perspective of
the NHS and the personal social services [13]. Health util-
ity values associated with each arm of the trial will be cal-
culated from the responses to the EQ-5D questionnaire.
Information relating to healthcare resource use associated
with the procedures and associated complications and
events during the trial period will be collected. Unit costs
for all healthcare resource use will be obtained from
routinely collected data and the literature to estimate the
total costs associated with resource use in each arm of the
trial. All costs and quality-adjusted life years (QALYs) will
be discounted at the currently recommended rate. Cost-
utility analyses will be carried out at two and four years
post-randomisation.
Regression analysis will be used to adjust the estimates
for relevant covariates, in conformity with the clinical ana-
lysis. Cost-effectiveness will be expressed as incremental
cost per QALY gained. The 95% confidence limits for the
difference in mean costs between arms and for the incre-
mental cost-effectiveness ratios will be calculated using
non-parametric bootstrap methods. In addition, the long-
term cost-effectiveness of the intervention will be esti-
mated by modelling. A probabilistic decision model will
be developed to estimate the subsequent health status
and costs beyond the period of the trial until the
Figure 2 FEMME study schema. HMB, heavy menstrual bleeding; MRI, magnetic resonance imaging; PBAC, Pictorial Blood Loss Assessment
Chart; UAE, uterine artery embolisation; UFS-QoL, Uterine Fibroid Symptom Quality-of-Life questionnaire.
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primarily by data extrapolation from this trial. Extensive
sensitivity analyses will be conducted to explore areas of
structural uncertainty in the analyses. Parameter uncer-
tainty, including that relating to heterogeneity of the pre-
specified subgroups, will be handled by using probabilistic
sensitivity analysis and presented using cost-effectiveness
curves.Sample size
The sample size for the trial is based around the primary
outcome measure of the total HRQL score taken from the
UFS-QoL questionnaire, and is informed by the results of
the pilot study at St George’s Hospital [11]. The mean dif-
ference seen here from the 118 patients who provided
questionnaire responses at twelve months was 12 points
in favour of myomectomy, with a standard deviation of 22
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equivalent to approximately 0.5 standard deviations (rounded
downwards to be conservative). To detect a difference of
this size (a moderate effect [14]) with 90% power (P = 0.05)
would require 86 patients in each group (172 in total).
Whilst the number of women expected to become preg-
nant before the primary outcome time of two years is ex-
pected to be low (10% or less), some provision needs to be
made for these women as not all questions on the UFS-
QoL will be still relevant. Additionally, a further 10% has
also been added to account for loss to follow-up (including
withdrawals). Thus, the final target sample size has been
inflated to 216 patients.
Data management and quality assurance
Data protection
Data will be stored and analysed in accordance with the
Data Protection Act 1998, plus any other relevant legis-
lation. Completed forms returned to the trials office will
be stored securely in a locked filing cabinet within a safe
haven office. There is a strictly enforced hierarchical ac-
cess policy which ensures that research staff (including
those at local sites) only have access to the electronic in-
formation which is necessary for them to perform their
duties, for example, allowing patients to be contacted for
follow-up or allowing data checks and validation.
Confidentiality
Personal and sensitive data will be collected directly from
trial participants and their hospital notes. Participants will
be informed about the transfer of this information to the
FEMME study office at Birmingham Clinical Trials Unit
(BCTU) and asked for their consent. With the patient’s
consent, their full name, date of birth, NHS or Community
Health Index number, address, postcode, hospital number,
GP details, and the participant’s telephone number and
e-mail address will be collected at trial entry. This will
allow direct contact with the participant and enable tra-
cing of non-responders to assist with long-term follow-up.
Patients will be identified using only their unique trial
number to verify identify on the data collection forms and
in any correspondence between the FEMME study office
and the participating site. Consent forms will be collected
by the FEMME study office and stored securely in the trials
master file. These forms will be available to various regula-
tory bodies for inspection upon request. These data will
be entered onto a secure computer database, either dir-
ectly by the local site via the internet using secure socket
layer (SSL) encryption technology, or indirectly from paper
forms by FEMME study office staff. Access control will en-
sure that local trials staff will only be able to view informa-
tion relating to participants at their site.
Blood samples, which have been transferred from local
centres to the University of Birmingham’s Human TissueRepository will only be identified by a code containing
the participant’s trial number, the treatment they were
randomized to, the time-point at which the bloods were
taken, and whether the samples were drawn on days
two, three, or four of the participant’s menstrual cycle.
Central laboratory staff will not have access to personal
or clinical trial data.
All personal information received in a paper format
for the trial will be held securely in locked filing cabinets
in a safe haven office and treated as strictly confidential
according to BCTU policies. All staff involved in the
FEMME study, be they clinical, academic, or employees
of BCTU, share the same duty of care to prevent un-
authorised disclosure of personal information. No data
that could be used to identify an individual will be pub-
lished. Personal data recorded on all documents will be
regarded as strictly confidential and will be handled and
stored in accordance with the Data Protection Act 1998
and any amendments.
Ethical requirements: Multicentre ethical approval for
the FEMME trial was granted by the Coventry and War-
wickshire REC on 15 June 2011 (reference number: 11/
WM/0149). The study will be performed in accordance
with the principles stated in the Declaration of Helsinki
[15]. Study procedures will be guided by the standards
outlined in the Guidelines for Good Clinical Practice in
Clinical Trials [16].
Monitoring of all types of adverse event
All types of adverse event which occur to participants in
the FEMME trial will be reported as soon as possible after
the clinician becomes aware of the event. An adverse
events form should be completed as fully as possible and
sent via fax to the trials office. This form will include an as-
sessment of causality. Upon receipt, the trials office will log
details of the adverse event on that patient’s record on the
central trials database and forward an anonymised copy of
the form to the sponsor and the Chief Investigator. Anon-
ymised details of all adverse events will be presented to the
DMC for scrutiny each time they meet. These anonymised
details will be reported to the REC annually.
Trial administration
Sponsor
The University of Oxford, Wellington Square, Oxford, OX1
2JD.
Trial Management Group
The Trial Management Group (TMG) is responsible for
the overall design and conduct of the study, analysis of the
data, and reporting and dissemination of results. It will act
on the advice of the Trial Steering Committee (TSC), the
DMC, and the funders (National Institute for Health
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[NIHR HTA]).
Membership of the Trial Management Group
Professor Klim McPherson (University of Oxford) is the
Chair and Chief Investigator. Professor Isaac Manyonda
(St. George’s Hospital, London), Professor Mary-Ann
Lumsden (Glasgow Royal Infirmary), Professor Jonathan
Moss (Gartnavel Hospital, Glasgow), and Professor
Anna-Maria Belli (St. George’s Hospital, London) are
Clinical Lead Investigators. Dr Jane Daniels (Birmingham
Clinical Trials Unit, Birmingham) and Mr Lee Middleton
(Birmingham Clinical Trials Unit, Birmingham) are
responsible for trial management. Professor Olivia Wu
(University of Glasgow) is responsible for health economics.
Trial Steering Committee
The TSC will provide independent overall supervision of
the trial. The members of the FEMME TSC are: Professor
Siladityta Bhattacharya (Chair; Aberdeen Royal Infirmary)
Professor Hilary Critchley (University of Edinburgh), Dr
Tony Nicholson (Leeds Teaching Hospital N.H.S. Trust),
and Ms Allison Hirst (University of Oxford).
Data Monitoring Committee
The primary role of the DMC is to ensure patient safety
and treatment efficacy whilst the trial is ongoing. At in-
tervals specified by the DMC the senior trial statistician
will provide confidential interim analysis of all available
data, alongside anonymised reports of any adverse events
suffered by participants in the trial. This will be reviewed
by the DMC who will advise the TSC if the trial should
continue as it is, continue with modifications, or be halted
due to futility, safety concerns, or overwhelming benefit.
The TSC will then decide whether to close or modify any
part of the trial. Unless this happens then no one other
than the trial statisticians (who supplied the confidential
analysis) and the members of the DMC will be made
aware of the results of the interim analysis.
The members of the FEMME DMC are: Professor
Doug Altman (Chair; University of Oxford), Professor
Jim Thornton (Queens Medical Centre, Nottingham),
and Dr. John Reidy (London).
Trial status
The FEMME trial is currently recruiting.
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